Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients with Advanced Breast and Gastrointestinal Tumors
Diseases and Conditions Researched
Gastrointestinal Tumors; Metastatic Breast Cancer
What is the purpose of this trial?The purpose of this study is to find the maximum and optimally tolerated dose of the combination of two drugs. The two drugs are Sorafenib and Capecitabine. The drug Sorafenib is an approved drug which is used to treat certain cancers. The drug Capecitabine is approved to treat patients with advanced breast cancer as well as early stage colon cancer. However, the combination of Sorafenib and Capecitabine is not FDA approved.
Click here for detailed participation information for this trial.
|Sponsors:||Bayer Pharmaceuticals; Yale Cancer Center|
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.